交易 Arcutis Biotherapeutics, Inc. - ARQT 差价合约

交易条件

• 类型: 差价合约
• 点差: 0.09
• 长仓隔夜仓息调整: -0.02174%
• 短仓隔夜仓息调整: -0.00049%
• 隔夜调整仓息时间: 22:00 (UTC)
• 货币: USD
• 最低成交量: 1
• 保证金: 50.00%
• 证券交易所: United States of America
• 交易佣金: 0%
• 保证止损溢价: 1%

主要统计数据

• 前收盘价: 26.56
• 开仓: 26.46
• 1 年变化: 107.53%
• 日区间: 26.46 - 27.15

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.